ArticleEndocrine2025
Association between alpha-lipoic acid use and macrovascular complications in patients with diabetic neuropathy.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlpha-lipoic acid (ALA) is an antioxidant used for the treatment of diabetic neuropathy in some countries. However, its potential impact on macrovascular complications remains unclear. This study examined the association between ALA use and cardiovascular (CV) outcomes and mortality in individuals with diabetes.
methodsA retrospective cohort study was conducted using the Korean National Health Insurance Service Health Screening Cohort data. Participants aged 40–79 years diagnosed with diabetic neuropathy between 2011 and 2015 were followed until December 2019. ALA users were defined as those prescribed ALA for ≥ 6 months. Propensity score matching balanced baseline characteristics, and Cox proportional hazards models evaluated the associations between ALA use and myocardial infarction (MI), stroke, diabetic foot ulcer, amputation, CV mortality, and all-cause mortality.
resultsA total of 8,740 participants (4,370 ALA users, 4,370 non-users) were included after matching. Over a median follow-up of 8.0 years, ALA use was associated with a lower risk of MI (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74–0.98), CV mortality (HR 0.73, 95% CI 0.55–0.96), and all-cause mortality (HR 0.82, 95% CI 0.72–0.93), while no significant associations were observed for stroke, diabetic foot ulcer, or amputation. MI risk reduction was more pronounced in those with a high Charlson comorbidity index. In a dose-response analysis of ALA users, a higher cumulative defined daily dose within the first year was significantly associated with a greater reduction in the risks of MI, CV mortality, and all-cause mortality (P for trend = 0.004, 0.011, and < 0.001, respectively).
conclusionALA use was associated with a reduced risk of MI and mortality in a dose-dependent manner. This suggests a potential protective role of ALA against macrovascular complications in patients with diabetic neuropathy.
Indexed as
Identifiers
40956474What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.